Aspira Pathlab & Diagnostics Limited Overview
| Field | Detail |
|---|---|
| Entity profiled | Aspira Pathlab & Diagnostics Limited (same entity as the one on the input list; no relisting or merger) |
| Legal name | Aspira Pathlab & Diagnostics Limited |
| Former name | Utkal Soap Products Limited (name changed 16 November 2016) |
| Date of incorporation | 3 July 1973 |
| Original state of registration | West Bengal (registered office moved to Maharashtra by order dated 18 November 2016) |
| Corporate Identification Number (CIN) | L85100MH1973PLC289209 |
| Registrar of Companies | RoC Mumbai |
| Registered office | Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (West), Mumbai 400 086, Maharashtra, India |
| Corporate office (as disclosed in 2019 filings) | Plot No. 6, RPT House, Sector 24, Turbhe, Navi Mumbai 400 703 (current status not re-verified) |
| Primary listing | BSE Limited. Scrip code 540788; Security ID ASPIRA |
| Other tickers | Yahoo: ASPIRA.BO; Reuters: ASPR.BO; some broker sites show NSE symbol "ASPIRA" |
| Historical listings | Calcutta Stock Exchange and Metropolitan Stock Exchange of India (both delisted) |
| ISIN | INE500C01017 |
| CUSIP | Not applicable (Indian security) |
| Face value | ₹10 per share |
| Shares outstanding | 1,02,93,000 equity shares (10.293 million). Equity share capital ₹10.29 Cr per the open-offer filing. One company-registry aggregator shows paid-up capital of ₹15.79 Cr against authorised capital of ₹35.00 Cr. This discrepancy is unreconciled and could reflect a post-June-2026 allotment or an aggregator error. |
| Fiscal year end | 31 March |
| Statutory auditor | refer to the FY2025-26 Annual Report |
| Registrar and Transfer Agent | Link Intime (India) Pvt Ltd per FY2021-22 Annual Report (previously Sharex Dynamic (India) Pvt Ltd in FY2018-19) |
| Banker (FY2021-22 AR) | Bank of Baroda |
| Website | www.aspiradiagnostics.com |
| Brand taglines | "Predict • Prevent • Protect"; "India's First Fully Integrated Lab" (company letterhead) |
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Employees (count) | — | — | 141 |
The 141 figure is PitchBook's profile count as of 2026.
Market Value (Latest)
| Metric | Value |
|---|---|
| Closing share price (BSE, 19 Oct 2026) | ₹114.95 |
| Market capitalisation (derived: ₹114.95 × 1.0293 Cr shares) | approx. ₹118 Cr (approx. USD 14 million) |
| 52-week high / low (as of mid-2026) | ₹135.88 / ₹49.00 |
| Promoter holding (June 2026) | 46.58% |
Aspira Pathlab & Diagnostics is a Mumbai-based micro-cap pathology and radiology services company. It operates through a shell-company route: a 1973 West Bengal soap manufacturer, Utkal Soap Products, was repurposed in 2016 by acquiring the running business of Ankur Pathology Laboratory. The company runs diagnostic centres concentrated in Mumbai, chiefly Ghatkopar and the eastern suburbs. Its services span pathology (biochemistry, haematology, histopathology, microbiology, immunology, virology, cytology), radiology (X-ray, ultrasound), and cardiology investigations. It serves walk-in and home-collection patients (B2C), plus hospitals, laboratories and corporates (B2B), including a growing Hospital Lab Management (HLM) offer. With FY2026 revenue of ₹24.98 Cr and near-breakeven profit, Aspira is a sub-scale regional player in a market dominated by national chains such as Dr Lal PathLabs and Metropolis. In 2026 its ownership was reshaped by a ₹55-per-share SEBI open offer that consolidated control with the Bhanushali–Mange family group. The company is now planning a rights issue of up to ₹65 Cr.
What the Company Does
Aspira's exchange-filed description says it is engaged in running, owning, managing and administering diagnostic centres. Its principal activities are pathology investigation services, radiology investigation services and related healthcare services at diagnostic centres in Mumbai. Its corporate profile describes it as a pathology specialist serving individual patients, hospitals, other healthcare providers and businesses. The profile says the company is built on technological automation, a patient-centric approach and dependable results. It also states an intention to establish itself as a strong regional player before scaling up. The company claims a "pan-India presence" in some profile text, but the operating disclosures point to a Mumbai and Maharashtra concentration. We treat the regional description as the accurate one.
Business Model
The company operates a classic hub-and-spoke diagnostics model:
Hub (processing laboratory): a central lab in Mumbai where samples are processed on automated analysers. Company materials emphasise IT integration to cut human error and track samples.
Spokes (collection network): owned diagnostic centres, franchise or partner collection points, and home sample collection. One data provider states the company operates "over 600 centres" and added 91 locations in FY2024-25. These are almost certainly collection or touch points rather than full-service laboratories.
B2B channel: referral testing for hospitals, nursing homes, clinics and smaller laboratories, plus Hospital Lab Management (HLM). Under HLM, Aspira runs in-house laboratories for hospitals. Management commentary says it is targeting newly set-up hospitals and laboratories.
Digital initiatives: cited by management: a chatbot, website upgrades, a patient-engagement platform and customer-service improvements.
Revenue Model
| Revenue type | Description | Disclosed share |
|---|---|---|
| Fee-for-service testing (B2C) | Per-test or per-package fees from walk-in and home-collection patients | — |
| B2B referral testing | Per-test fees billed to hospitals, clinics and labs, usually at discounted B2B rates | — |
| Hospital Lab Management (HLM) | Service contracts to run hospital laboratories; may include revenue share or fixed fees | — |
| Corporate and preventive health | Wellness packages for employers and individuals | — |
| Product, subscription, licensing | None identified | 0% |
All revenue is service revenue. There is no product, subscription or licensing income.
Value Chain Position
Aspira sits at the service-delivery end of the diagnostics value chain. Upstream are in-vitro diagnostic (IVD) equipment and reagent suppliers, typically multinationals such as Roche, Abbott, Siemens Healthineers, Beckman Coulter and Sysmex. Downstream are referring doctors, hospitals and patients. With about ₹25 Cr of revenue, Aspira has limited bargaining power against reagent suppliers. It competes for doctor referrals against chains that are 50 to 100 times its size.
Customer Types and End-Markets
| Customer type | Notes |
|---|---|
| Individual patients | Walk-in and home collection in Mumbai suburbs |
| Referring physicians | The traditional standalone-lab referral model in Mumbai |
| Hospitals and nursing homes | B2B referral plus HLM |
| Other laboratories | Outsourced specialised tests |
| Corporates and businesses | Pre-employment and wellness testing |
The end-market is the Indian diagnostics services market, specifically the Mumbai Metropolitan Region.
Independent Characterisation
Aspira is best described as a single-city, single-segment, sub-scale diagnostics operator with a listed-shell history. Its economics are highly sensitive to volume. Depreciation, much of it on right-of-use lease assets, runs at about ₹1.5 Cr per year against about ₹25 Cr of revenue. Small revenue swings therefore move it between double-digit operating margins and losses. This is visible in FY2024 (loss), FY2025 (profit) and FY2026 (breakeven). The FY2022 peak profit reflected COVID-era testing demand. The company's strategic future is now tied to the newly consolidated promoter group and the use of the proposed ₹65 Cr rights issue. That sum is more than 2.5 times annual revenue and about half the current market capitalisation.
Strategy
Stated Strategic Themes (from company descriptions and management commentary)
-
Regional consolidation before scale-up. Build a strong regional (Mumbai and Maharashtra) franchise before expanding further.
-
Hospital Lab Management (HLM) focus. Target newly established hospitals and laboratories.
-
Technology and automation. Use automated analysers and IT-integrated sample tracking to cut human error.
-
Digital patient engagement. Chatbot, website upgrade, patient-engagement platform and customer service.
-
Preventive positioning. The "Predict • Prevent • Protect" brand architecture.
Initiatives in the Last 24 Months
| Date | Initiative | Status / significance |
|---|---|---|
| Apr 2024 | Formed Aspira DNA Diagnostics Gujarat LLP (associate) for molecular / DNA diagnostics outside Mumbai | Reversed; strike-off decided May 2026 |
| FY2025 | Network expansion of 91 locations (reported) | Drove the 66.6% revenue rebound |
| FY2025–26 | Digital engagement tools (chatbot, platform) | Ongoing; no metrics disclosed |
| Feb 2026 | Related-party transaction of up to ₹5 Cr with Yashraj Research Foundation | Approved by Board; nature of services not disclosed; went to AGM for approval |
| Apr–Jun 2026 | Change of control via ₹55-per-share open offer | Completed; promoter stake 46.58% |
| Aug–Sep 2026 | Leadership transition to Nikunj Mange as MD | Completed Sep 2026 |
| 12 Sep 2026 | Rights issue of up to ₹65 Cr (equity or convertible instruments) | Approved by Board; record date, price and objects pending |
Medium-Term Targets and Guidance
The company has issued no quantitative financial guidance, medium-term targets, or cost-programme targets. No investor-day materials exist. No ESG or sustainability commitments have been publicly quantified.
Products & Services
Aspira does not publish a priced test menu in its regulatory filings. The catalogue below is compiled from the company's corporate descriptions and the service categories it lists. Specific test counts, pricing and launch years are not publicly disclosed in the filings reviewed.
Pathology Services
| Offering | Description / capabilities | Target customer | Pricing model |
|---|---|---|---|
| Clinical biochemistry | Routine chemistry panels (liver, kidney, lipid, glucose, electrolytes) on automated analysers | B2C, B2B, HLM | Per test / package |
| Haematology | CBC, coagulation and related blood tests | B2C, B2B | Per test |
| Histopathology | Tissue biopsy processing and reporting | Hospitals, surgeons | Per specimen |
| Cytology | Pap smears, fluid cytology, FNAC | Gynaecologists, hospitals | Per specimen |
| Microbiology | Cultures and sensitivity testing | Hospitals, clinicians | Per test |
| Immunochemistry / immunology | Hormones, tumour markers, autoimmune panels | B2C, B2B | Per test |
| Virology / serology | Infectious-disease serology; molecular testing capacity during COVID-19 (inferred from the FY2021–22 revenue spike; not separately disclosed) | B2C, B2B, government | Per test |
| DNA / molecular (Gujarat LLP initiative) | Aspira DNA Diagnostics Gujarat LLP was formed in 2024, apparently for DNA-based testing; now being struck off | B2B | — |
Radiology and Cardiology
| Offering | Description | Target customer |
|---|---|---|
| X-ray | Digital radiography at diagnostic centres | Walk-in patients, referrals |
| Ultrasound sonography | Abdominal, obstetric and general USG | Walk-in patients, gynaecologists |
| Cardiology investigations | Cardiac diagnostics (e.g., ECG; full menu not disclosed) | Preventive packages, physicians |
Channel and Service Offerings
| Offering | Description |
|---|---|
| Diagnostic centres | Owned centres in Mumbai (Ghatkopar flagship near the railway station) |
| Collection network | Reported 600+ centres or touch points, with 91 added in FY2025 (aggregator claim) |
| Home sample collection | Doorstep phlebotomy (typical of the model; specific disclosure limited) |
| Hospital Lab Management (HLM) | Strategic focus area per management commentary; targets newly opened hospitals and labs |
| Preventive health packages | Bundled wellness profiles under the "Predict • Prevent • Protect" positioning |
| Digital patient engagement | Chatbot, website, patient-engagement platform (management-stated initiatives) |
Quality Credentials
A third-party (non-company) web page claims NABL and CAP accreditation. This could not be confirmed against an NABL certificate or company filing in this research run.
Financial Narrative
Sources: S&P Global Market Intelligence via StockAnalysis (income statement, balance sheet and cash flow, FY2022–FY2026, last updated 12 Aug 2026). Screener (consolidated FY2024–FY2025). Capital Market / Business Standard and Medical Buyer (FY2026 headline). Ratios are derived by this analyst from those figures. FY2021 revenue and profit are back-calculated from S&P's reported FY2022 growth rates (28.52% revenue, 222.91% net income) and are marked as derived.
Income Statement (₹ Cr)
Notes:
-
FY2021 (derived): revenue approx. ₹15.21 Cr; net income approx. ₹1.38 Cr.
-
Screener's consolidated FY2025 operating profit is ₹3.13 Cr (14.23% OPM) and FY2024 is -₹1.55 Cr. These differ from the S&P-derived EBITDA because of classification of other income and associate share. Both are shown for transparency.
-
FY2026 net profit was ₹5.13 lakh per the AGM disclosure (₹0.05 Cr).
-
The zero tax charge reflects accumulated losses: retained earnings were -₹12.0 Cr at FY2026.
Balance Sheet (₹ Cr, at 31 March)
Data-conflict note on equity. S&P shows "Total Common Equity" of ₹7.30 Cr (FY2026) and separately "Shareholders' Equity" of ₹12.23 Cr, a gap of about ₹4.9 Cr that S&P does not explain. Business Standard shows book value of ₹7.03 per share, consistent with the ₹7.3 Cr figure. Screener's P/B of about 9x implies book value nearer ₹12 per share, consistent with the ₹12.2 Cr figure. Ratios below use the ₹7.3 Cr common-equity figure, as it ties to share capital (₹10.29 Cr) plus premium (₹9.03 Cr) less accumulated deficit (₹12.02 Cr). Readers should confirm against the audited FY2026 balance sheet.
Goodwill. Goodwill of ₹2.65 Cr has sat on the books since the 2016 Ankur Pathology acquisition. It rose to ₹3.31 Cr in FY2026, alongside a ₹0.75 Cr cash acquisition outflow. The target of that FY2026 acquisition is not identified in the sources reviewed. It is possibly linked to the LLP buy-in or a centre or business purchase.
Key Ratios (Derived)
Net debt / EBITDA for FY2024 is NA because EBITDA was negative. Screener independently reports debtor days improving from 42.1 to 25.3, consistent with the derived figures.
Quarterly Run-Rate (₹ Cr)
Sources: Kotak Neo, IndMoney, roic.ai (Q2 FY2026), ScanX (Q3 FY2026, Q1 FY2027), Medical Buyer / Capital Market (Q4 FY2026).
Conflicts:
-
ScanX gives Q3 FY2025 profit as ₹0.38 Cr (₹37.66 lakh) against Kotak Neo's ₹0.31 Cr.
-
Univest gives Q4 FY2025 profit as ₹0.35 Cr against Capital Market's ₹0.72 Cr.
-
ScanX gives Q1 FY2026 revenue as ₹5.25 Cr (₹524.80 lakh) and profit as ₹0.47 Cr (₹46.94 lakh).
-
Q1 FY2027 revenue was ₹6.17 Cr (₹616.91 lakh), up about 17.6% YoY, while the net loss was ₹3.77 lakh. ScanX's headline said "revenue down 16%," but its own data show revenue up. The data figure is adopted here.
Commentary on Trends, Inflections and Drivers
Revenue. The five-year revenue line traces a COVID boom, normalisation, and a rebuild. FY2022 revenue of ₹19.54 Cr was lifted by pandemic testing. As this faded, revenue fell 26% in FY2023 and a further 8.7% in FY2024, to ₹13.21 Cr. The FY2025 rebound of 66.6%, to ₹22.00 Cr, was the inflection. It coincided with the reported addition of 91 locations and management's pivot toward HLM and B2B. FY2026 growth slowed to 13.6% (₹24.98 Cr). Within that, Q2 FY2026 was unusually strong at ₹8.09 Cr, possibly a lumpy B2B or institutional contract (not explained in filings reviewed), and Q3 FY2026 fell to ₹5.12 Cr. Quarterly volatility of this kind is typical of a company where a few institutional accounts can move the top line.
Profitability. Margins are dominated by operating leverage. Gross margin swung from 51% (FY2022) to 26% (FY2024) and back to about 41–44%. The FY2026 problem was below gross profit. Operating expenses excluding COGS jumped 36%, from ₹7.65 Cr to ₹10.42 Cr, while gross profit rose only 6.6%. This erased the FY2025 EBIT of ₹2.06 Cr. Likely contributors include network-expansion costs, staff costs, and costs around the change of control (open offer, governance changes, company-secretary turnover). The company has not provided a line-item explanation. Q3 and Q4 FY2026 losses of ₹1.56 Cr and ₹0.69 Cr confirm that the cost base outgrew revenue in the second half. Q1 FY2027 showed near-breakeven (-₹0.04 Cr) on higher revenue, suggesting some stabilisation.
Balance sheet. The balance sheet is small and modestly geared. Cash and short-term investments of about ₹1.7 Cr leave net debt of about ₹1.6 Cr. Working capital has shrunk from ₹5.4 Cr to ₹1.5 Cr, and the current ratio has fallen from 4.0x to 1.5x. Part of this is genuine improvement in collections: debtor days fell from 84 to 25. Part of it is cash being redeployed into long-term investments (₹2.79 Cr) and goodwill. The accumulated deficit of about ₹12 Cr means the company cannot pay dividends without first rebuilding reserves.
Cash flow. Cash generation is positive but thin. Operating cash flow has been positive in four of five years, at ₹1.0–2.0 Cr. However, after Ind AS 116 lease payments, which are effectively rent, true free cash flow was negative in FY2023 and FY2026. The business is not self-funding growth at scale. This frames the ₹65 Cr rights issue as a step-change in capital base rather than incremental funding.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Segment Margins & Growth (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Diagnostics services revenue (INR Cr) | 13.21 | 22.00 | 24.98 |
Segment operating income, EBIT (INR Cr) | -2.73 | 2.06 | -0.08 |
Segment pre-tax income (INR Cr) | -2.67 | 2.02 | 0.05 |
Segment EBIT margin (%) | -20.6 | 9.4 | -0.3 |
YoY revenue growth (%) | -8.7 | 66.6 | 13.6 |
Share of total revenue (%) | 100 | 100 | 100 |
Service Line Details
| Service line | Content |
|---|---|
Pathology | Biochemistry, haematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology |
Radiology | X-ray, ultrasound sonography |
Cardiology | Cardiac diagnostic investigations |
Hospital Lab Management (HLM) | Outsourced operation of hospital labs |
Preventive and corporate health | Packages and wellness programmes |
Group Entities
| Entity | Relationship | Status |
|---|---|---|
Aspira Pathlab & Diagnostics Ltd | Listed parent and operating company | Active |
Aspira DNA Diagnostics Gujarat LLP | Associate formed 2 Apr 2024; company to acquire 100% and strike off (announced May 2026) | Being wound up |
Yashraj Biotechnology Ltd | Historical promoter-group shareholder (17.52% in 2018; 13.95% in Mar 2021); shared CEO in 2017–19 | — |
Yashraj Research Foundation | Counterparty to the ₹5 Cr related-party transaction approved by the Board on 10 Feb 2026 | Related party |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 19.54 | 14.46 | 13.21 | 22.00 | 24.98 |
Revenue growth YoY (%) | 28.5 | -26.0 | -8.7 | 66.6 | 13.6 |
Cost of revenue (INR Cr) | 9.56 | 8.86 | 9.79 | 12.29 | 14.63 |
Gross profit (INR Cr) | 9.98 | 5.59 | 3.42 | 9.71 | 10.35 |
Operating expenses excl. COGS (INR Cr) | 5.24 | 5.59 | 6.14 | 7.65 | 10.42 |
Operating income, EBIT (INR Cr) | 4.74 | 0.01 | -2.73 | 2.06 | -0.08 |
Depreciation & amortisation (INR Cr) | 1.58 | 1.53 | 1.51 | 1.49 | 1.54 |
EBITDA, derived EBIT + D&A (INR Cr) | 6.32 | 1.54 | -1.21 | 3.55 | 1.46 |
Interest expense (INR Cr) | 0.31 | 0.37 | 0.32 | 0.31 | 0.39 |
Pre-tax income (INR Cr) | 4.46 | -0.09 | -2.67 | 2.02 | 0.05 |
Tax (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Net income (INR Cr) | 4.46 | -0.09 | -2.67 | 2.02 | 0.05 |
EPS basic, derived on 1.0293 Cr shares (INR) | 4.33 | -0.09 | -2.60 | 1.96 | 0.05 |
EPS diluted (INR) | 4.33 | -0.09 | -2.60 | 1.96 | 0.05 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 51.1 | 38.7 | 25.9 | 44.1 | 41.4 |
EBITDA margin (%) | 32.3 | 10.6 | -9.2 | 16.1 | 5.9 |
Operating (EBIT) margin (%) | 24.2 | 0.1 | -20.6 | 9.4 | -0.3 |
Pre-tax margin (%) | 22.8 | -0.6 | -20.2 | 9.2 | 0.2 |
Net margin (%) | 22.8 | -0.6 | -20.2 | 9.2 | 0.2 |
CAGR | Value | — | — | — | — |
Revenue CAGR FY2022–FY2026 (4 years) | 6.3% | — | — | — | — |
Revenue CAGR FY2021–FY2026 (5 years, FY2021 derived) | 10.4% | — | — | — | — |
Revenue CAGR FY2024–FY2026 (2 years) | 37.5% | — | — | — | — |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 18.14 | 17.34 | 14.71 | 17.51 | 18.51 |
Cash & short-term investments (INR Cr) | 1.64 | 2.35 | 1.38 | 2.14 | 1.68 |
Trade receivables (INR Cr) | 4.49 | 2.34 | 2.24 | 2.35 | 1.73 |
Inventory (INR Cr) | 0.41 | 0.40 | 0.45 | 0.51 | 0.70 |
Property, plant & equipment incl. right-of-use (INR Cr) | 6.82 | 5.31 | 4.12 | 3.86 | 3.88 |
Long-term investments (INR Cr) | 0 | 0 | 0 | 1.91 | 2.79 |
Goodwill & intangibles (INR Cr) | 2.75 | 2.70 | 2.67 | 2.67 | 3.32 |
Short-term debt incl. current lease liabilities (INR Cr) | 0.65 | 0.68 | 0.70 | 0.83 | 0.88 |
Long-term debt excl. leases (INR Cr) | 0.86 | 0.96 | 1.08 | 1.21 | 1.35 |
Long-term lease liabilities (INR Cr) | 2.42 | 1.68 | 1.01 | 1.16 | 1.09 |
Total debt incl. leases (INR Cr) | 3.92 | 3.31 | 2.78 | 3.20 | 3.32 |
Net debt (INR Cr) | 2.28 | 0.96 | 1.40 | 1.05 | 1.64 |
Total common equity (INR Cr) | 7.86 | 7.82 | 5.21 | 7.29 | 7.30 |
Working capital (INR Cr) | 5.36 | 4.27 | 2.28 | 2.99 | 1.47 |
Book value per share (INR) | 7.64 | 7.60 | 5.07 | 7.08 | 7.09 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 2.03 | -0.01 | 1.05 | 1.88 | 1.45 |
Capital expenditure (INR Cr) | -0.60 | -0.13 | -0.26 | -0.34 | -0.70 |
Free cash flow (INR Cr) | 1.43 | -0.14 | 0.79 | 1.53 | 0.76 |
Lease payments (INR Cr) | -0.59 | -0.62 | -0.70 | -0.78 | -0.89 |
FCF after lease payments (INR Cr) | 0.85 | -0.76 | 0.09 | 0.76 | -0.14 |
Cash acquisitions (INR Cr) | 0 | 0 | 0 | 0 | -0.75 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (INR Cr) | 0.17 | -0.79 | 0.24 | 0.95 | -0.49 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, net income / closing equity (%) | 56.7 | -1.1 | -51.2 | 27.8 | 0.7 |
ROA, net income / total assets (%) | 24.6 | -0.5 | -18.2 | 11.6 | 0.3 |
ROIC, EBIT / (equity + debt), zero tax (%) | 40.2 | 0.1 | -34.1 | 19.7 | -0.7 |
Current ratio (x) | 3.99 | 3.69 | 2.10 | 2.26 | 1.47 |
Debt/equity incl. leases (x) | 0.50 | 0.42 | 0.53 | 0.44 | 0.46 |
Net debt / EBITDA (x) | 0.36 | 0.63 | — | 0.30 | 1.12 |
Interest coverage, EBIT / interest (x) | 15.4 | 0.0 | -8.6 | 6.8 | -0.2 |
Asset turnover (x) | 1.08 | 0.83 | 0.90 | 1.26 | 1.35 |
Debtor days | 83.9 | 59.1 | 62.0 | 39.0 | 25.3 |
Inventory days, on COGS | 15.5 | 16.4 | 16.7 | 15.2 | 17.4 |
Payable days, on COGS | 23.3 | 14.2 | 27.1 | 21.9 | 28.4 |
Cash conversion cycle (days) | 76.1 | 61.3 | 51.6 | 32.3 | 14.3 |
Income Statement
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 | 8.09 | 5.12 | 6.52 | 6.17 |
Net profit (INR Cr) | -0.02 | 0.99 | 0.31 | 0.72 | 0.47 | 1.84 | -1.56 | -0.69 | -0.04 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India, total (INR Cr) | 13.21 | 22.00 | 24.98 |
Outside India (INR Cr) | 0 | 0 | 0 |
India growth YoY (%) | -8.7 | 66.6 | 13.6 |
Geography Overview
| Geography | Activity | Revenue disclosed |
|---|---|---|
Mumbai (Ghatkopar and eastern suburbs) | Registered office, flagship centre and lab operations | Not publicly disclosed (assumed to be the large majority) |
Navi Mumbai (Turbhe) | Corporate office per 2019 filings | Not applicable |
Wider Maharashtra | Collection network and B2B and HLM clients (inferred) | — |
Gujarat | Aspira DNA Diagnostics Gujarat LLP (2024), now being struck off | Not publicly disclosed (associate; equity-accounted loss of ₹0.05 Cr in FY2025 per S&P) |
“—” = not publicly disclosed.
Share Price & Returns
| Reference point | Price (INR) | Source |
|---|---|---|
19 Apr 2024 | 30.15 | Equitymaster |
27 Nov 2024 | 74.44 | IndMoney |
13 Sep 2025 | 62.00 | Kotak Securities |
19 Dec 2025 | 63.50 | ICICIdirect |
16 Jan 2026 | 67.00 | Business Standard |
21 Apr 2026 | 56.00 | Kotak Neo |
16 Jun 2026 | 117.60 | Value Research |
29 Jun 2026 | 130.60 | Trendlyne |
1 Oct 2026 | 131.25 | IIFL |
19 Oct 2026 | 114.95 | StockAnalysis |
Return period | Approx. return | Basis |
1-year, to Oct 2026 | about +85% | From about ₹62 (Sep 2025) to ₹114.95 |
3-year | Not precisely verified | Business Standard: +62% over 3 years to Jan 2026; since Apr 2024 (₹30.15) about +281% |
Lifetime low | ₹14.15 | Anand Rathi |
Valuation Multiples
| Multiple | Aspira | Peer context (aggregator snapshots, 2026) |
|---|---|---|
Market cap (INR Cr) | approx. 118 | Dr Lal approx. 32,259; Vijaya approx. 15,511 |
P/E on FY2026 EPS ₹0.05 (x) | approx. 2,300 | Dr Lal approx. 60x; Vijaya approx. 83x |
P/B on common equity ₹7.09/share (x) | approx. 16.2 | Peer median approx. 3.0x (Value Research) |
P/B on aggregator equity ₹11.89/share (x) | approx. 9.7 | Value Research shows 9.9x |
EV/Sales, EV approx. ₹120 Cr (x) | approx. 4.8 | MarketInOut: 5.47x at the Jul 2026 price |
EV/EBITDA on FY2026 EBITDA ₹1.46 Cr (x) | approx. 82 | MarketInOut: 70.7x; Dr Lal approx. 42x |
Capital Markets
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Key Events
| Event | Detail |
|---|---|
Nov 2016 preferential issue | 29,43,000 shares at ₹17 |
Sep 2026 rights issue (proposed) | Up to ₹65 Cr, equity or convertibles; price, ratio and record date pending |
Capital Markets — Moody's / S&P / Fitch
| Item | Status |
|---|---|
Moody's / S&P / Fitch | Not rated |
Domestic (CRISIL / ICRA / CARE) | None identified |
Debt maturity profile | Total debt ₹3.32 Cr (FY2026): current lease liabilities ₹0.88 Cr due within 12 months; long-term leases ₹1.09 Cr; long-term borrowings ₹1.35 Cr (lender and terms not disclosed; may be related-party) |
Analyst Conclusions
Management Guidance and Consensus
No quantitative guidance has been issued and no consensus exists. Qualitative direction includes regional consolidation, an HLM focus, digital engagement, and, implicitly, scale-up funded by the proposed rights issue.
Bull Case
-
Capital step-change. A fully subscribed ₹65 Cr rights issue would give a company with about ₹7 Cr of common equity the means to acquire Mumbai standalone labs or build HLM capacity. This could plausibly multiply revenue from the current ₹25 Cr base, much as the 2016 Ankur Pathology deal created the business.
-
Operating leverage is proven. In FY2025, revenue of ₹22 Cr produced 9.4% EBIT margin and ₹2.0 Cr PAT. Q1 FY2027 revenue of ₹6.17 Cr (annualising to about ₹25 Cr) was already near breakeven. Modest revenue growth with cost discipline could restore FY2025-level margins, untaxed thanks to accumulated losses.
-
Aligned, committed owners. The new promoter group invested ₹12.55 Cr in cash at ₹55 per share, now holds 46.58%, and continues buying on the open market. This suggests intent to build rather than extract value.
Bear Case
-
Structurally unprofitable at scale. FY2026 showed that growth (+13.6%) came with a 36% cost surge and a 97.6% profit fall. Two loss quarters indicate the business has not yet found a profitable growth formula against far larger rivals.
-
Governance and dilution. Concentrated control, a ₹5 Cr related-party arrangement with Yashraj Research Foundation, company-secretary turnover, and an undisclosed use of proceeds for a rights issue about half the market cap together create meaningful minority-shareholder risk.
-
Valuation disconnect. At about ₹115 the stock trades at roughly 2x the ₹55 offer price set only six months earlier, about 2,300x FY2026 EPS, 80x+ EV/EBITDA and 10–16x book. This prices in a transformation that has not begun, in an illiquid stock.
Key Catalysts and Monitorables (next 12 months)
| Catalyst / monitorable | What to watch |
|---|---|
| Rights issue terms | Price, ratio, record date and stated objects (acquisitions? related-party assets?); promoter subscription and renunciation |
| Q2 FY2027 results (Nov 2026) | Whether the cost base stabilises after the leadership change; revenue run-rate above ₹6 Cr per quarter |
| Clinical leadership | Appointment of a senior pathologist / medical director after Dr Shah's exit |
| Compliance officer appointment | Filling the CS vacancy |
| Related-party transactions | Actual flows to Yashraj entities versus the approved ₹5 Cr limit |
| HLM contract wins | Any named hospital contracts disclosed under Reg. 30 |
| Share capital reconciliation | Whether paid-up capital remains ₹10.29 Cr or has changed (registry shows ₹15.79 Cr) |
| Accreditation | Confirmation of NABL status |
Analyst Verdict
Aspira Pathlab & Diagnostics is a speculative special situation, not a diagnostics growth compounder. The underlying business is real but small. A Mumbai pathology and radiology operator turned over ₹24.98 Cr in FY2026, generates modestly positive operating cash, and has shown it can earn a high-single-digit operating margin when volumes cooperate, as in FY2025. It has also shown that margins evaporate quickly when costs run ahead of revenue: FY2026 profit fell 97.6%, with back-to-back loss quarters in the second half.
The investment case has shifted decisively from operations to ownership and capital. The Bhanushali–Mange group's ₹55 open offer gave it 46.58% control. The founder-MD has left, Nikunj Mange now runs the company, and a rights issue of up to ₹65 Cr is on the table, roughly nine times current common equity. Done well, this capital could fund a disciplined roll-up of Mumbai's fragmented standalone labs and an HLM platform, turning a sub-scale lab into a credible regional player. Done poorly, it could fund related-party asset purchases or unfocused expansion, diluting minorities in a stock with no institutional oversight.
The market has priced the optimistic version. At about ₹115, the shares trade at more than twice the price the controlling group paid six months ago, at multiples that only make sense if revenue and margins multiply. Disclosure quality is low, with no guidance, segment data or test-volume metrics, and related-party exposure has risen. For institutional capital, the stock is effectively uninvestable on liquidity and governance grounds until the rights-issue objects are published and at least two quarters of post-transition results are available. For risk-tolerant investors, the rights-issue offer document is the single most important document to read. The verdict is Neutral-to-Cautious / Speculative, with re-assessment triggered by the rights-issue terms and the Q2–Q3 FY2027 results.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation (latest disclosed) |
|---|---|---|---|---|
Nikunj Velji Mange | Managing Director (re-designation approved at 53rd AGM, 25 Sep 2026); previously Executive Director; promoter since Jun 2026 | — | Open-offer Acquirer 4; spouse Shraddha Nikunj Mange was the PAC | — |
Vaibhav Odhekar | Executive Director (regularised at 2026 AGM) | 2,026 | — | — |
Dr Pankaj Jashwant Shah | Former MD & CEO; resigned effective 3 Aug 2026 (personal reasons) | Executive Director from 1 Aug 2016; CEO from 13 Jun 2020; MD re-appointed for 3 years from 1 Aug 2022 | Pathologist; led the business since the 2016 Ankur Pathology acquisition | ₹6.0 million total (100% salary) per Simply Wall St (FY2025); held 4.86% of shares |
Chief Financial Officer | — | — | Not identified in sources reviewed | — |
Company Secretary & Compliance Officer | Resigned early 2026; successor not identified | — | — | — |
Dr C. P. Puri (historical) | CEO, 2017–2019 (also CEO of Yashraj Biotechnology) | 2017–2019 | Former Director, ICMR's National Institute for Research in Reproductive Health | Not applicable |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Independence | Notes |
|---|---|---|---|
Dr Haseeb A. Drabu | Chairman | Independent | Economist; former Finance Minister of Jammu & Kashmir and former Chairman of J&K Bank (public record) |
Nikunj Velji Mange | Managing Director | Executive / Promoter | See above |
Vaibhav Odhekar | Executive Director | Executive | Regularised Sep 2026 |
Manas Mengar (DIN 10218206) | Director | Independent | Appointed at 50th AGM, 26 Sep 2023 |
Avinash Mahajan | Director | Independent | Re-appointed for a 5-year term from 25 Sep 2022 (to 2027) |
Former Maharashtra public-health official (name not captured) | Director | Independent | Board-appointed 13 Aug 2022; career from Deputy Director to Director General, Maharashtra Health Services; prior WHO regional advisory roles per filing |
"Mangala" and "Subhash" (surnames not captured) | Directors | — | Listed by a company-registry aggregator as active directors |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Early 2026 | Company Secretary cum Compliance Officer resigned | During open-offer process |
11 Jun 2026 | Nikunj Mange and Jay Arvind Bhanushali reclassified as promoters | Post open offer, under SEBI rules |
3 Aug 2026 | Dr Pankaj Shah resigned as MD | Personal reasons; founder-operator exit after about 10 years |
25 Sep 2026 | Nikunj Mange re-designated MD; Vaibhav Odhekar regularised as Executive Director | New control group takes operating leadership |
Shareholding Trend
| Holder category | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
Promoter & promoter group (%) | 19.47 | 18.72 | 18.39 | 18.39 | 46.58 |
FII (%) | 0 | 0 | 0 | 0 | 0 |
DII / mutual funds (%) | 0 | 0 | 0 | 0 | 0 |
Public (%) | 80.53 | 81.28 | 81.61 | 81.61 | 53.42 |
Major Shareholders
| Holder | Stake | As of | Category |
|---|---|---|---|
Deepali Arvind Bhanushali | 8.6% | Mar 2026 (pre-offer; post-offer higher) | Promoter |
Rinku Vinod Bhanushali | 8.02% | Mar 2026 | Public (largest public holder) |
Jay Arvind Bhanushali | 7.27% | Sep 2026 | Promoter (open-market purchases Sep 2026) |
Arvind Karsandas Bhanushali | — | — | Promoter / lead acquirer |
Dr Pankaj Shah | 4.86% | 2,025 | Insider (former MD) |
Nikunj Velji Mange | 2.14% pre-offer | 2025–26 | Promoter |
Shraddha Nikunj Mange | 1.46% pre-offer | 2025–26 | Promoter group (PAC) |
Raj Arvind Bhanushali | 0.76% pre-offer | 2025–26 | Promoter |
Yashraj Biotechnology Ltd | — | — | Historical promoter-group entity |
Competitive Landscape
Peer Comparison FY2025
| Competitor | Type | Relevance to Aspira | Approx. scale (FY2025 revenue) | Market cap (aggregator snapshot, 2026) |
|---|---|---|---|---|
Dr Lal PathLabs | Listed national chain | Strong Mumbai presence via B2C and B2B network | approx. ₹2,460 Cr | approx. ₹32,259 Cr |
Metropolis Healthcare | Listed national chain, Mumbai-headquartered | Most direct home-market rival | approx. ₹1,330 Cr | Not captured |
Thyrocare Technologies | Listed national chain, Navi Mumbai-headquartered | B2B / franchise wholesale testing | approx. ₹690 Cr | Not captured |
Vijaya Diagnostic Centre | Listed regional chain (South India) | Model peer for a regional strategy | approx. ₹680 Cr | approx. ₹15,511 Cr |
Krsnaa Diagnostics | Listed (PPP / government-focused) | Competes for institutional / HLM-type contracts | approx. ₹720 Cr | Not captured |
Agilus Diagnostics (ex-SRL, Fortis group) | Unlisted subsidiary of listed Fortis | Hospital-lab and B2B competitor | — | Not applicable |
Apollo Diagnostics | Hospital-group diagnostics | Hospital and retail competitor | — | Not applicable |
Suburban Diagnostics | Mumbai regional chain | Direct Mumbai B2C competitor | — | Not applicable |
Neuberg Diagnostics | Private national network | B2B / reference lab | — | Not applicable |
Tata 1mg Labs, Healthians, Redcliffe Labs, Orange Health | Digital-first home-collection players | Compete for B2C home collection | — | Not applicable |
Standalone neighbourhood labs (Mumbai) | Fragmented local operators | Largest competitive set by count | Not applicable | Not applicable |
Peer Comparison FY2026
| Metric | Aspira (FY2026) | Dr Lal PathLabs (FY2025, approx.) | Metropolis (FY2025, approx.) | Thyrocare (FY2025, approx.) |
|---|---|---|---|---|
Revenue (INR Cr) | 24.98 | approx. 2,460 | approx. 1,330 | approx. 690 |
Revenue growth (%) | 13.6 | approx. 10–11 | approx. 10–11 | approx. 14–15 |
EBITDA margin (%) | 5.9 | approx. 27–28 | approx. 24–25 | approx. 26–28 |
Net margin (%) | 0.2 | approx. 19–20 | approx. 10–11 | approx. 14–15 |
R&D intensity (%) | — | Not material | Not material | Not material |
Market cap (INR Cr) | approx. 118 | approx. 32,000 | Not captured | Not captured |
“—” = not publicly disclosed.



